High levels of CD9 evaluated with this antibody were associated with poor prognosis in gastric cancer (111), while the association with good prognosis was found for mesothelioma, cervical and prostate cancer (75, 105, 116). This evidence concerns the gene CD9 and Familial prostate cancer.